PHIO (STOCKS)
Phio Pharmaceuticals Corp. Common Stock
$1.240000
+0.030000 (+2.48%)
Prev close: $1.210000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Robert J. Bitterman
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $14.44M
- Employees
- 5
- P/E (TTM)
- -0.80
- P/B (TTM)
- 0.70
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.25 | $-0.35 | +0.0938 | +27.05% |
|
Sep 2025 (Q3)
|
$-0.44 | $-0.46 | +0.0190 | +4.14% |
|
Jun 2025 (Q2)
|
$-0.45 | $-0.37 | -0.0828 | -22.55% |
|
Dec 2024 (Q4)
|
$-0.85 | $-1.25 | +0.4046 | +32.25% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $9.22M |
| Research and Development | $4.62M |
| Other Operating Expenses | $4.60M |
| Operating Income/Loss | -$9.22M |
| Income/Loss From Continuing Operations After Tax | -$8.70M |
| Income/Loss From Continuing Operations Before Tax | -$8.70M |
| Income Tax Expense/Benefit | $0.00 |
| Income Tax Expense/Benefit, Current | $0.00 |
| Net Income/Loss | -$8.70M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$8.70M |
| Net Income/Loss Available To Common Stockholders, Basic | -$8.70M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.45 |
| Basic Average Shares | 5,984,017 |
| Assets | $21.49M |
| Current Assets | $21.48M |
| Noncurrent Assets | $11.00K |
| Fixed Assets | $11.00K |
| Liabilities | $1.34M |
| Current Liabilities | $1.34M |
| Accounts Payable | $435.00K |
| Other Current Liabilities | $905.00K |
| Noncurrent Liabilities | $0.00 |
| Equity | $20.15M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $20.15M |
| Liabilities And Equity | $21.49M |
| Net Cash Flow From Operating Activities | -$7.98M |
| Net Cash Flow From Operating Activities, Continuing | -$7.98M |
| Net Cash Flow From Investing Activities | -$12.00K |
| Net Cash Flow From Investing Activities, Continuing | -$12.00K |
| Net Cash Flow From Financing Activities | $23.64M |
| Net Cash Flow From Financing Activities, Continuing | $23.64M |
| Net Cash Flow | $15.65M |
| Net Cash Flow, Continuing | $15.65M |
| Comprehensive Income/Loss | -$8.70M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$8.70M |
| Other Comprehensive Income/Loss | $0.00 |